Johnson & Johnson (NYSE:JNJ) touted first-in-human clinical data today for its investigational HIV vaccine in development by its subsidiary, Janssen Pharmaceutical.
The Phase I/IIa trial enrolled 393 healthy volunteers. According to the data, the vaccine was well-tolerated and triggered an HIV antibody response in 100% of participants.
Get the full story at our sister site, Drug Delivery Business News.
The post J&J touts first-in-human data for HIV vaccine appeared first on MassDevice.